INTRODUCTION
Cardiovascular diseases (CVD) remain the main cause of death in the majority of countries (1, 2) . (version 2012) have promoted the treatment of all the reversible risk factors identified and the appropriate management of the raised blood pressure (BP) per se (3) . The recent decrease in cardiovascular mortality in high-income countries is associated with a rise in the numbers of patients living with cardiovascular disease and the wider use of preventive drugs. In the past decades most European countries have developed administrative databases to monitor drug utilization by measuring volume and expenditures of medicines and the quality of prescribing on a national level. The ultimate goal of drug utilization research is an assessment of drug therapy rationality. Only few data were published on prevalence, awareness and management of CVD in Lithuania. The aim of our study was to evaluate the trends and pattern of the use of cardiovascular (CV) medicines in Lithuania in [2003] [2004] [2005] [2006] [2007] [2008] [2009] [2010] [2011] [2012] .
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MATERIALS AND METHODS
The use of reimbursed medicines, acting on the cardiovascular system, during the period of ten years -2003-2012 was studied. CV drugs were classified according to the Anatomical-Therapeutic-Chemical (ATC) classification. The list of analysed CV medicines groups and cardiovascular drugs is presented in the Table. The data of purchased reimbursed medicines was retrieved from the SVEIDRA database of the National Health Insurance Fund (NHIF). Drug utilization was calculated using the Anatomical Therapeutic Chemical / Defined Daily Dose (ATC/DDD) methodology, and data was expressed as a number of DDD per 1 000 inhabitants per day (DDD/TID), using the ATC/DDD Index 2014 (4, 5, 6) . 
RESULTS
The utilization of CV drugs in
C09D -ARB, combinations
Losartan and HCT (C09DA01); eprosartan and HCT (C09DA02); valsartan and HCT (C09DA03); telmisartan and HCT (C09DA07); olmesartan medoxomil and HCT (C09DA08); amlodipine and valsartan (C09DB01); olmesartan medoxomil and amlodipine (C09DB02).
C10 -Lipid modifying agents
Simvastatin (C10AA01); pravastatin (C10AA03); fluvastatin (C10AA04); atorvastatin (C10AA05); rosuvastatin (C10AA07).
study period (G%) = 162%; annual growth percentage (AG%) = 16.2%).
The most used medicines were the agents acting on the renin-angiotensin system (RAS), followed by beta blocking agents (BBs) and calcium channel blockers (CCBs).
The consumption of antihypertensive medicines went from 4.7 to 23.9 DDD/TID (G% = 406%). The utilization of moxonidine grew by between 2 to 16.1 DDD/TID. The utilization of doxazosin also increased 3.5 times during the study period (2.2-7.8 DDD/TID). The consumption of methyldopa (<0.01 DDD/TID) and prazosin (<0.1 DDD/TID) was very low.
The consumption of plain diuretics was stable and low in Lithuania (9.4-15.2 DDD/TI). The utilization of indapamide was rather stable during the study period The group of agents acting on RAS was the most consumed CV medicines. We analyzed separately the utilization of ACEI and ARB, plain and combinations. The utilization of the plain ACEI increased from 66 DDD/TID in 2003 to 114.8 DDD/TID in 2008 followed by the reduction to 89.2 DDD/TID in 2012 (G% = 35.1). This decrease was compensated by an augmentation in consumption of combined preparations with ACEI (5.2-38.6 DDD/ TID; G% = 648.7), plain ARB (0.5-42 DDD/TID; G% = 8 615.7) and ARB combinations (1.4-12.9 DDD/TID; G% = 809.4) (Fig. 2) .
Ramipril was the most consumed medicine of all CV drugs (14.8-44.3 DDD/TID). The utilization of previously very popular enalapril decreased from 35.8 to 6.1 DDD/TID. This study showed an increasing utilization of perindopril (1.5-19.6 DDD/TID), quinapril (2.2-11.6 DDD/TID) and zofenopril 
DISCUSSION
The aim of this study was to evaluate the trends and pattern of utilization of CV medicines in Lithuania in 2003-2012. The idea was that the total amount and pattern of CV drugs used in Lithuania can relatively reflect the aggressiveness in arterial hypertension and other CVD treatment. Evidence favouring the administration of BP-lowering drugs to reduce the risk of major clinical CV outcomes (fatal and nonfatal stroke, myocardial infarction (MI), heart failure and other CV deaths) in hypertensive individuals results from a number of RCTs, recent meta-analysis (7) (8) (9) (10) (11) . In the 2007 and 2013 versions of the Guidelines of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC) it was concluded that the main benefits of antihypertensive treatment are due to lowering of BP per se and are largely independent of the drugs employed (12, 13) .
Only few data was published on prevalence, awareness and management of arterial hypertension, and impact on health-related quality of life in Lithuania (14, 15) . Previous studies found out that the most frequently prescribed drugs had been ACEI (75.3% of patients), BBs (61.1%), diuretics (47.6%), CCBs (36.1%), alpha-receptor blockers (8.4%) (16) . In addition, our data showed high consumption of centrally active antihypertensive agents and alpha-receptor blockers in Lithuania (3.51-6.79% of all prescribed CV drugs). A similar trend could be observed in Latvia where the utilization of these drugs also reached 3.7-5% of all CV drugs (17) . On the contrary, the utilization of alpha-receptor blockers is very low in Scandinavian countries -less than 1% in Sweden, Denmark and Finland -and in Estonia (18, 19, 20, 21, 23) . Alpha-receptor blockers are recommended as the third-line therapy or in multiple drug combinations when other treatment options failed (24) . None of studies have shown superiority of these medicines compared to others. Future analysis on the patient level has to be performed for the explanation of this phenomenon in Lithuania.
Diuretics remain the cornerstone of antihypertensive treatment and are recommended by the ESH/ ESC Guidelines as the first-choice drugs used either as monotherapy or in some combinations (13) . The evidence proves that thiazides reduce mortality (RR 0.89, 95% CI 0.83, 0.96), incidence of stroke (RR 0.63, 95% CI 0.57, 0.71), coronary heart disease (CHD) (RR 0.84, 95% CI 0.75, 0.95) and cardiovascular events (RR 0.70, 95% CI 0.66, 0.76) (9) . The use of plain diuretic medicinal products was not frequent in Lithuania despite guidelines on hypertension treatment. The use of plain diuretics made up about 5.75% of all prescribed CV drugs DDD/TID compared with 22.5-16.5% in Sweden in 2006-2012 (18) and 36-18.4% in Denmark (19) in 2003-2012. We found out that the reduction of plain diuretics utilization was compensated by increased use of the combined preparation of diuretics and other antihypertensive agents, reaching on the average 11.3% of all used CV drugs DDD/TID in Lithuania in 2012. The same trend of increased utilization of the combinations was observed in Norway, Denmark, Estonia and Finland (8.9-11% of all CV medicines DDD/TID) (19) (20) (21) (22) . Only in Sweden the utilization of combined preparations remained low and stable (4% of all CV medicines DDD/TID) in 2006-2012 (18) .
The increasing utilization of beta blockers was registered during the study period (on the average 9.3-14.9% of all CV drugs). A similar utilization rate was observed in Scandinavia and other Baltic countries (7-15%) (17) (18) (19) (20) (21) (22) (23) .
The utilization of calcium antagonists was decreasing in Lithuania from 2008 composing 14.4-9.6% of used all DDD/TIDs. The use of CCBs was higher and is still increasing in all Scandinavian countries (12.8-16 .3%) and in Latvia (16.8-20 .1%) (17) (18) (19) (20) (21) (22) (23) . Some data shows that CCB may reduce incidence of cardiovascular events (RR 0.71, 95% CI 0.57, 0.87), but not CHD (RR 0.77 95% CI 0.55, 1.09) or cardiovascular mortality (RR 0.86, 95% CI 0.68, 1.09) (9) , cardiovascular complications in hypertensive diabetics (25) and in patients with metabolic syndrome (26) .
The ACEI are the most popular CV medicines. Clinical trials showed that they have not only lower BP, but also improve outcomes and survival in patients with heart failure, with prior MI, and in patients with diabetes type 1 and kidney diseases (9, 27, 28) . Our data showed that ACEI were the mostly prescribed CV drugs in Lithuania (49.1%-36.3% of all CV drugs DDD/TID), although decrease in the use of plain ACEI was noticed that was compensated by using combined ACEI preparations (10.97% of all CV drugs in 2012). The same tendency was observed in Latvia and Estonia: plain ACEI made up 20.7-30.3% and ACEI combination 6.5-20.9% of all CV drugs DDD/TID (17, 21) . Data from other countries confirmed lower utilization of plain ACEI (14.7-18.4% of all CV medicines DDD/TID in Scandinavia) and combined ACEI (1-1.5% in Sweden, 1.2-3.8% in Denmark, Finland and Norway) (18, 19, 20, 22) .
The consumption of ARB, plain and combinations was increasing in our country. The plain ARBs compose 11.9% and ARB combinations make up 3.3% of all CV drugs DDD/TID. An increase in the use of ARB is also noticed in other countries despite prescribing restrictions by the authorities (29) .
An extremely low use of lipid modifying agents in Lithuania is difficult to explain. On the contrary, the utilization of statins in Western Europe was 10-15 times higher, e. g. it is more than 100 DDD/ TID in Scandinavian countries. Although the recent guidelines recommend prescribing statins very early for the primary prophylaxis, debates are ongoing whether such "statinization" of population is rational and justifiable (30, 31, 32) . Furthermore, an ecological study performed in Sweden did not show that increase in the use of statins has any impact on CV mortality (33).
Our study has a number of limitations. We have not analyzed the utilization of the CVM at the patient level, thus we are not able to say whether all purchased medicines were utilized, whether patients were compliant, and whether drugs were prescribed according to the guidelines. We also have not analysed what indications CV drugs were prescribed for. Nonetheless, despite the limitations our study shows the trends and patterns of CV drug use. Further studies are needed to find out whether changes in the use of CV medicines has any impact on mortality from CV diseases.
CONCLUSIONS
The utilization of CV medicines increased in Lithuania in 2003-2012. The ACEI group held the first position during the study period, but utilization of combined preparations is growing every year. An extremely low utilization of lipid modifying agents, plain diuretics and high consumption of alpha-receptor blockers showed the need of some actions on changing the prescribing pattern of CVM in order to achieve better quality of care.
